Table:
Study name (reference)	No patients	BB used	Description	Main findings	Additional findings and comments
MDC (Waagstein et al., 1993)	383	Metoprolol	HF secondary to Dilated Cardiomyopathy (EF <40%)	34% decrease in mortality or need for transplantation	No significant difference in mortality alone
MERIT-HF (Hjalmarson et al., 2000)	3991	Metoprolol succinate	Mild-moderate HF (EF <40%) NYHA II-IV	<34% decrease in all cause mortality	<39% decrease in cardiac death and non-fatal MI
CIBIS (CIBIS Investigators and Committees, 1994)	641	Bisoprolol	Moderate HF (EF <40%) NYHA III-IV	No significant difference in mortality	Significant improvement of functional status of the patients
CIBIS II (CIBIS-II Investigators, 1999)	2647	Bisoprolol	Moderate HF (EF <35%) NYHA III-IV	32% decrease risk of mortality and hospitalization for HF	Greatest effects in patients with ischaemic HF and NYHA III at baseline
CIBIS III (Willenheimer et al., 2005)	1010	Bisoprolol (vs. enalapril)	Mild moderate HF (EF <35%) NYHA II-III	Non-inferiority of bisoprolol vs enalapril in reducing mortality as first treatment in ITT	Non-inferiority of bisoprolol was not proven in per-protocol analysis
US Carvedilol study (Packer et al., 1996)	1094	Carvedilol	Mild moderate HF NYHA II-IV	65% mortality reduction	38% reduction in death or hospitalization for cardiovascular reasons
COPERNICUS (Packer et al., 2002)	2289	Carvedilol	Severe HF (EF <25%) NYHA III-IV	35% in risk of death	27% decrease death or hospitalization for a cardiovascular reason
CAPRICORN (The CAPRICORN Investigators, 2001)	1959	Carvedilol	Patients with recent MI and left ventricular dysfunction (EF <40%)	23% reduction in mortality	No significant difference in primary endpoint (all-cause mortality or hospitalization for cardiovascular problems)
COMET (Poole-Wilson et al., 2003)	3029	Carvedilol vs. Metoprolol tartrate	Mild moderate HF (EF <35%) NYHA II-IV	17% decrease in carvedilol- vs. metoprolol- arm	Concerns about metoprolol formulation
BEST (BEST Investigators, 2001)	2708	Bucindolol	Mild moderate HF (EF <35%) NYHA III-IV	No significant overall survival benefit	Reduction in mortality in patients homozygous for Arg389 (subsequent pharmacogenetic analysis)
SENIORS (Flather et al., 2005)	2128	Nebivolol	Mild moderate HF (EF <35% in last 6-months) Age >70yrs	14% reduction mortality and hospitalizations	Significant increase of LVEF and decrease in end-systolic volume

Encode the diagram in Markdown syntax.

| Study name (reference) | No patients | BB used | Description | Main findings | Additional findings and comments | 
 | --- | --- | --- | --- | --- | --- | 
 | MDC (Waagstein et al., 1993) | 383 | Metoprolol | HF secondary to Dilated Cardiomyopathy (EF <40%) | 34% decrease in mortality or need for transplantation | No significant difference in mortality alone | 
 | MERIT-HF (Hjalmarson et al., 2000) | 3991 | Metoprolol succinate | Mild-moderate HF (EF <40%) NYHA II-IV | <34% decrease in all cause mortality | <39% decrease in cardiac death and non-fatal MI | 
 | CIBIS (CIBIS Investigators and Committees, 1994) | 641 | Bisoprolol | Moderate HF (EF <40%) NYHA III-IV | No significant difference in mortality | Significant improvement of functional status of the patients | 
 | CIBIS II (CIBIS-II Investigators, 1999) | 2647 | Bisoprolol | Moderate HF (EF <35%) NYHA III-IV | 32% decrease risk of mortality and hospitalization for HF | Greatest effects in patients with ischaemic HF and NYHA III at baseline | 
 | CIBIS III (Willenheimer et al., 2005) | 1010 | Bisoprolol (vs. enalapril) | Mild moderate HF (EF <35%) NYHA II-III | Non-inferiority of bisoprolol vs enalapril in reducing mortality as first treatment in ITT | Non-inferiority of bisoprolol was not proven in per-protocol analysis | 
 | US Carvedilol study (Packer et al., 1996) | 1094 | Carvedilol | Mild moderate HF NYHA II-IV | 65% mortality reduction | 38% reduction in death or hospitalization for cardiovascular reasons | 
 | COPERNICUS (Packer et al., 2002) | 2289 | Carvedilol | Severe HF (EF <25%) NYHA III-IV | 35% in risk of death | 27% decrease death or hospitalization for a cardiovascular reason | 
 | CAPRICORN (The CAPRICORN Investigators, 2001) | 1959 | Carvedilol | Patients with recent MI and left ventricular dysfunction (EF <40%) | 23% reduction in mortality | No significant difference in primary endpoint (all-cause mortality or hospitalization for cardiovascular problems) | 
 | COMET (Poole-Wilson et al., 2003) | 3029 | Carvedilol vs. Metoprolol tartrate | Mild moderate HF (EF <35%) NYHA II-IV | 17% decrease in carvedilol- vs. metoprolol- arm | Concerns about metoprolol formulation | 
 | BEST (BEST Investigators, 2001) | 2708 | Bucindolol | Mild moderate HF (EF <35%) NYHA III-IV | No significant overall survival benefit | Reduction in mortality in patients homozygous for Arg389 (subsequent pharmacogenetic analysis) | 
 | SENIORS (Flather et al., 2005) | 2128 | Nebivolol | Mild moderate HF (EF <35% in last 6-months) Age >70yrs | 14% reduction mortality and hospitalizations | Significant increase of LVEF and decrease in end-systolic volume |